Evidence map›Paper›PMID 26160407›Full record

ArticleRetrovirology2015

HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation.

Jonathan M O Rawson, Sean R Landman, Cavan S Reilly, Louis M Mansky

Abstract read
In one paragraph

Article in Retrovirology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. The evolution of SARS-CoV-2.Nature reviews. Microbiology · 2023
    Review
  13. Article
  14. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  15. Article
  16. Article
  17. The frequency of defective genes inJournal of ginseng research · 2021
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jonathan M O RawsonInstitute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA. rawso018@umn.edu.
Sean R LandmanDepartment of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, USA. landman@cs.umn.edu.
Cavan S ReillyInstitute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA. cavanr@biostat.umn.edu.
Louis M ManskyInstitute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA. mansky@umn.edu.

Funding

Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
HIV Reverse Transcriptase-Mediated MutagenesisR01GM105876 · NIGMS · UNIVERSITY OF MINNESOTA · PI KIM, BAEK, MANSKY, LOUIS M. · 2013 to 2016
$2.4M
Quantitative Investigation of HIV MutagenesisF31DA035720 · NIDA · UNIVERSITY OF MINNESOTA · PI RAWSON, JONATHAN · 2015 to 2015
$28k
NIAID NIH HHS T32 AI083196NIDA NIH HHS F31 DA035720NIGMS NIH HHS R01 GM105876
6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus type 2 (HIV-2) is often distinguished clinically by lower viral loads, reduced transmissibility, and longer asymptomatic periods than for human immunodeficiency virus type 1 (HIV-1). Differences in the mutation frequencies of HIV-1 and HIV-2 have been hypothesized to contribute to the attenuated progression of HIV-2 observed clinically.

resultsTo address this hypothesis, we performed Illumina sequencing of multiple amplicons prepared from cells infected with HIV-1 or HIV-2, resulting in ~4.7 million read pairs and the identification of ~200,000 mutations after data processing. We observed that: (1) HIV-2 displayed significantly lower total mutation, substitution, and transition mutation frequencies than that of HIV-1, along with a mutation spectrum markedly less biased toward G-to-A transitions, (2) G-to-A hypermutation consistent with the activity of APOBEC3 proteins was observed for both HIV-1 and HIV-2 despite the presence of Vif, (3) G-to-A hypermutation was significantly higher for HIV-1 than for HIV-2, and (4) HIV-1 and HIV-2 total mutation frequencies were not significantly different in the absence of G-to-A hypermutants.

conclusionsTaken together, these data demonstrate that HIV-2 exhibits a distinct mutational spectrum and a lower mutation frequency relative to HIV-1. However, the observed differences were primarily due to reduced levels of G-to-A hypermutation for HIV-2. These findings suggest that HIV-2 may be less susceptible than HIV-1 to APOBEC3-mediated hypermutation, but that the fidelities of other mutational sources (such as reverse transcriptase) are relatively similar for HIV-1 and HIV-2. Overall, these data imply that differences in replication fidelity are likely not a major contributing factor to the unique clinical features of HIV-2 infection.

Indexed as

Mutation RatePoint MutationAPOBEC DeaminasesCell Line, TumorCytidine DeaminaseCytosine DeaminaseGenes, vprHigh-Throughput Nucleotide SequencingHIV-1HIV-2HIV InfectionsHumansSequence Analysis, DNAvif Gene Products, Human Immunodeficiency VirusVirus ReplicationAPOBEC3 proteins, humanAPOBEC DeaminasesCytidine DeaminaseCytosine Deaminasevif Gene Products, Human Immunodeficiency Virus

Identifiers

PMID26160407
PMCPMC4496919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.